---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021555"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:18:10.059835+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harrow Q3 revenue $71.6M (+45% YoY), net income $1.0M; VEVYE revenue $22.6M (+22% QoQ)

## Summary
- Total revenue $71.6M (+45% YoY); GAAP net income $1.0M vs loss $4.2M YoY; Adj. EBITDA $22.7M vs $8.8M
- VEVYE revenue $22.6M (+22% QoQ); national DED market share 10.5% (up 2.7pp); coverage agreements with largest PBM effective Jan 2026
- IHEEZO revenue $21.9M (+70% YoY); on track to exceed $50M annual revenue by year-end 2025
- Agreed to acquire Melt Pharmaceuticals (MELT-300) for non-opioid sedation; refinancing cut interest ~$3M/yr, added $50M liquidity

## SEC filing metadata
- accession: 0001493152-25-021555
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/0001493152-25-021555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021555
- JSON: https://secwatch.observer/filing/0001493152-25-021555.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.